Merck cancels trial of melanoma treatment due to immune-mediated adverse events
An increased rate of discontinuation due to immune-mediated adverse events was seen in the trial's coformulation arm.
An increased rate of discontinuation due to immune-mediated adverse events was seen in the trial's coformulation arm.
PhaseV will analyse NeuroSense’s Phase II ALS trial data, and results from these will inform Phase III trial design, enrolment, and cost-effectiveness.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
MMI pioneers Symani Surgical System in first US cases
“Defensibility” key for AI-centric small biotechs seeking investment
Klineo wins €2m to advance AI patient recruitment platform
Hyperfine starts enrolment in portable imaging workflow study